Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
23/06/2025 18:33
June 23 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A: ACTINIUM PHARMACEUTICALS INC - REPORTS NEW DATA ON ATNM-400 PROSTATE CANCER CANDIDATE ACTINIUM PHARMACEUTICALS INC - ATNM-400 SHOWS SUPERIOR EFFICACY TO XTANDI IN PROSTATE CANCER Source text: ID:nPnZvLCda Further company coverage: ATNM.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities